(Q34017133)

30 July 2017

1 reference

title

Clarithromycin in the management of community-acquired pneumonia (English)

1 reference

30 July 2017

1 reference

1 reference

McCarty JM

1

1 reference

30 July 2017

publication date

1 March 2000

1 reference

30 July 2017

published in

Clinical Therapeutics

1 reference

30 July 2017

volume

22

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

281-94; discussion 265

1 reference

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

The cost of treating community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Risk factors for pneumonia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Prospective study of the aetiology and outcome of pneumonia in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Hospital study of adult community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Community-acquired pneumonia: impact of immune status

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Risk of pneumonia in patients previously treated in hospital for pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Practical considerations and guidelines for the management of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Azithromycin and clarithromycin: overview and comparison with erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

The postantibiotic effect of clarithromycin and its major human metabolite, 14-hydroxy clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Antibiotics for pneumonia therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Prevalence and resistance mechanisms of common bacterial respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Pneumococcal resistance to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980033-8

7 January 2021

10.1016/S0149-2918(00)80033-8

Identifiers

DOI

1 reference

release_mmcopmmty5haxevhedngydk32q

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mmcopmmty5haxevhedngydk32q

24 November 2022

mapped directly with Wikidata item

1 reference